0.912
Precedente Chiudi:
$0.91
Aprire:
$0.92
Volume 24 ore:
73,258
Relative Volume:
0.50
Capitalizzazione di mercato:
$51.49M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-0.5124
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
+11.22%
1M Prestazione:
+4.10%
6M Prestazione:
-24.94%
1 anno Prestazione:
-84.36%
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Confronta PRLD con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
PRLD
Prelude Therapeutics Inc
|
0.912 | 51.38M | 0 | -131.52M | -107.56M | -1.78 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2022-07-29 | Iniziato | Jefferies | Buy |
2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
2021-04-26 | Iniziato | H.C. Wainwright | Buy |
2021-03-09 | Iniziato | Barclays | Overweight |
2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
2020-10-20 | Iniziato | BofA Securities | Buy |
2020-10-20 | Iniziato | Goldman | Neutral |
2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
Will Prelude Therapeutics Incorporated stock split in the near futureExplosive trading opportunities - jammulinksnews.com
What analysts say about Prelude Therapeutics Incorporated stockRapid wealth accumulation - Autocar Professional
Is Prelude Therapeutics Incorporated a good long term investmentExplosive capital appreciation - Autocar Professional
Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study - TipRanks
Prelude Therapeutics Incorporated Stock Analysis and ForecastExplosive capital gains - jammulinksnews.com
What drives Prelude Therapeutics Incorporated stock priceDynamic profit opportunities - jammulinksnews.com
what makes prelude therapeutics incorporated stock price move sharplyFree Investment Community - Newser
Is Prelude Therapeutics Incorporated stock a good hedge against inflation10x Return With Managed Risk - Newser
What makes Prelude Therapeutics Incorporated stock price move sharplyFree Access to Investment Community - Newser
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionPro Trader Stock Focus - Newser
How Prelude Therapeutics Incorporated stock performs during market volatilityFree Smart Investment Opportunities - Newser
Prelude Therapeutics’ PRT7732 Study: A Potential Game-Changer for SMARCA4 Mutations - TipRanks
Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors - TipRanks
Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study - TipRanks
Transcript : Prelude Therapeutics Incorporated Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09 - MarketScreener
Baker Bros. Advisors LP Increases Stake in Prelude Therapeutics Inc. - GuruFocus
Two Sigma Investments LP Purchases 174,906 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLC - Defense World
20,572 Shares in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Purchased by BNP Paribas Financial Markets - Defense World
Two Sigma Advisers LP Raises Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Phio Pharmaceuticals Advances 30-Drug Cancer Portfolio as Phase 1b Trial Shows Promise - Stock Titan
Prelude Therapeutics describes new SMARCA2 and SMARCA4 degradation inducers - BioWorld MedTech
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Northern Trust Corp - Defense World
Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025 - MyChesCo
Prelude Therapeutics to Participate in Upcoming Healthcare Confe - GuruFocus
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences | PRLD Stock News - GuruFocus
Precision Oncology Pioneer Prelude Therapeutics Sets Stage for Major June Healthcare Conference Updates - Stock Titan
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences - Yahoo Finance
Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges - Investing.com India
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):